Table 2.
Risk of experiencing clinical events in patients with NVAF who are receiving apixaban and patients not on treatment
| Medical event | Apixaban (rate per 100 PY) [26, 30] | Hazard ratio, no treatment versus apixaban [33] | No treatment (rate per 100 PY) [26, 30, 33] |
|---|---|---|---|
| Ischemic stroke among paroxysmal AF patients | 1.070 (0.672–1.577)a, b | 3.846 (2.703–5.556) | 4.11 |
| Ischemic stroke among permanent AF patients | 1.354 (0.851–1.966)a, b | 5.21 | |
| Systemic embolism | 0.090 (0.0889–0.091) | 0.346 | |
| Intracranial hemorrhage | 0.33 (0.247–0.426) | 0.526 (0.154–1.563) | 0.174 |
| Other major bleeds | 2.472 (1.785–3.294)a | 0.806 (0.442–1.429) | 1.993 |
| Clinically relevant non-major bleeds | 2.083 (2.063–2.113) | 1.679 | |
| Myocardial infarction | 0.530 (0.515–0.545) | 2.273 (0.971–5.000) | 1.205 |
| Other cardiovascular hospitalization | 10.460 (10.448–10.472) | 1.155 (0.992–1.345) | 12.081 |
| Other treatment discontinuation | 13.177 (12.442–13.932) | N/A | |
NA not applicable, NVAF non-valvular atrial fibrillation, PY patient year
aDependent on CHADS2 distribution, see Online Resource for further details
bARISTOTLE reported on the ischemic stroke risk among all patients enrolled in the trial. To determine the risk of ischemic stroke in patients with paroxysmal AF and permanent AF the distribution of patients among these characteristics in ARISTOTLE (15.31% vs 84.69%) [30] was used alongside estimates that the HR of stroke among paroxysmal patient as compared with permanent patients is 0.79 [28]